Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial

LESSONS LEARNED. Evidence has suggested that capecitabine‐cisplatin is similar or possibly superior to S‐1‐cisplatin in terms of safety and efficacy for Japanese patients with advanced gastric cancer (AGC). As far as we are aware, our study is the first randomized trial of two regimens consisting of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Kawakami, Hisato, Takeno, Atsushi, Endo, Shunji, Makari, Yoichi, Kawada, Junji, Taniguchi, Hirokazu, Tamura, Shigeyuki, Sugimoto, Naotoshi, Kimura, Yutaka, Tamura, Takao, Fujitani, Kazumasa, Sakai, Daisuke, Shimokawa, Toshio, Kurokawa, Yukinori, Satoh, Taroh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2018
Aiheet:
Clinical Trial Results
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292554/
https://ncbi.nlm.nih.gov/pubmed/30115736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0175
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia